Methylphenidate extended release - ALZA

Drug Profile

Methylphenidate extended release - ALZA

Alternative Names: Concerta; JNS-001; Oros® methylphenidate

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ALZA Corporation
  • Developer Janssen Pharmaceutical KK
  • Class Phenylacetates; Piperidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Adrenergic receptor modulators; Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder

Most Recent Events

  • 09 Jun 2014 Registered and launched for Attention-deficit hyperactivity disorder (In adults) in Japan before June 2014 (PO)
  • 24 May 2013 Preregistration for Attention-deficit hyperactivity disorder (in adults) in Japan (PO)
  • 01 Apr 2012 Johnson & Johnson completes phase III trials in Attention-deficit hyperactivity disorder in Japan (NCT01323192, NCT01357993)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top